Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Completed PHASE4 INTERVENTIONAL NCT05286554

Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Hormonal milieu during implantation is crucial to embryo-endometrium interaction and to the viability of the conceptus. Alterations in the peri-implantation environment are considered to impair perinatal outcomes in intracytoplasmic sperm injection (ICSI) therapy. GnRH-a is a new and promising modality for LPS. Regimens for using GnRH-a in LPS, including single mid-luteal bolus or the addition of a GnRH-a to progesterone supplementation, have been recently suggested. The aim of this study is to evaluate the impact of addition of mid-luteal single-dose or multiple-dose GnRH agonist to the routine luteal phase support in patients undergoing ICSI cycles using GnRH antagonist protocol.

Interventions

Name: gonadotropin releasing hormone-agonist
Type: DRUG
Description: subcutaneous injection
Name: Progesterone
Type: DRUG
Description: vaginal suppositories (400 mg twice daily) starting on the day after oocyte retrieval and will be continued till pregnancy assessed by serum β-HCG 15 days after ICSI, and if pregnant, for 10 weeks of gestation.

Primary Outcomes

Measure: Clinical pregnancy rate
TimeFrame: 2 weeks after positive pregnancy test
Description: Calculated as the number of clinical pregnancies (Presence of an intrauterine gestational sac with embryonic cardiac activity observed by vaginal ultrasound) divided by the number of embryo transfer procedures.

Trial Information

NCT ID

NCT05286554

Status

Completed

Study Type

INTERVENTIONAL

Phases

PHASE4

Sponsor

Alexandria University

Last Updated

December 15, 2025